课题基金 / 基金详情

Toward effective targeted therapies for Acute Myeloid Leukaemia (AML)

Toward effective targeted therapies for Acute Myeloid Leukaemia (AML)
寻找治疗急性髓系白血病(AML)的有效靶向疗法
批准号:
nhmrc : 1126843
负责人:
A/Pr Andrew Wei
金额:
$37.58万
依托单位:
依托单位国家:
澳大利亚
项目类别:
Project Grants
财政年份:
2017
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2017-01-01 至 2019-12-31

项目摘要

项目成果

A/Pr Andrew Wei的其他基金

相似基金

相关文献

中文摘要
翻译
急性髓性白血病(AML)的标准化疗是高毒性的,40多年来没有改变。我们将进行世界上第一项临床试验,将ABT-199(Venetoclax)靶向BCL 2纳入AML的标准治疗。第二项计划将探索小分子抑制剂同时靶向BCL 2及其相关伴侣MCL 1的潜力,以创建AML的“无化疗”方案。这些研究预示着AML治疗的新时代。
英文摘要
Standard chemotherapy for acute myeloid leukaemia (AML) is highly toxic, and has not changed in over 40 years. We will conduct a world-first clinical trial incorporating ABT-199 (Venetoclax) to target BCL2 into the standard-of-care treatment for AML. A second initiative will explore the potential for small molecule inhibitors to simultaneously target both BCL2 and its related partner MCL1, to create a “chemotherapy-free” regimen for AML. These studies promise to herald a new era in AML therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Examining the contribution of mutant DNMT3a in the development and sustained growth of Acute Myeloid Leukaemia
  • 批准号:
    nhmrc : GNT1145728
  • 项目类别:
    Project Grants
  • 资助金额:
    $82.09万
  • 财政年份:
    2018
  • 负责人:
    A/Pr Andrew Wei
  • 依托单位:
Examining the contribution of mutant DNMT3a in the development and sustained growth of Acute Myeloid Leukaemia
Translational Research Program to Advance Clinical Outcomes in Acute Myeloid Leukaemia
  • 批准号:
    nhmrc : 1141460
  • 项目类别:
    Practitioner Fellowships
  • 资助金额:
    $27.89万
  • 财政年份:
    2018
  • 负责人:
    A/Pr Andrew Wei
  • 依托单位:
Toward effective targeted therapies for Acute Myeloid Leukaemia (AML)
  • 批准号:
    nhmrc : GNT1126843
  • 项目类别:
    Project Grants
  • 资助金额:
    $55.13万
  • 财政年份:
    2017
  • 负责人:
    A/Pr Andrew Wei
  • 依托单位:
国内基金
海外基金
多跳无线 MESH 网络中 QoS 保障算法的研究设计和性能分析